论文部分内容阅读
大肠癌是严重威胁人类健康的一种疾病。欲提高大肠癌的长期生存率则应提高其早期诊断率和准确、客观地判断预后是关键所在。近年来,随着分子生物学技术的发展和应用,大肠癌微小转移灶的检测已逐渐被人们了解和掌握。国内外不少学者应用免疫组化法、PCR法、放射性同位索示踪法等大大提高了检测的敏感性和特异性,在大肠癌患者的标本及/或活体上证实了淋巴结中存在的微小转移灶,并因此改变了患者的分期和治疗方案及预后,对指导临床工作有重要意义。本文就近年对大肠癌患者手术切除的肿瘤组织和淋巴结用p53蛋白及细胞角蛋白(CK)和第二代
Colorectal cancer is a disease that seriously threatens human health. To improve the long-term survival rate of colorectal cancer, it is critical to improve its early diagnosis rate and accurately and objectively determine prognosis. In recent years, with the development and application of molecular biology techniques, detection of micrometastases in colorectal cancer has gradually been understood and mastered by people. Many scholars at home and abroad have greatly improved the sensitivity and specificity of detection using immunohistochemistry, PCR, and radioisotope tracer methods, and confirmed the presence of microscopic lymph nodes in specimens and/or living bodies of colorectal cancer patients. Metastasis, and therefore changes in the patient’s staging and treatment options and prognosis, are important for guiding clinical work. This paper presents the use of p53 protein and cytokeratin (CK) and second generation of tumor tissues and lymph nodes surgically resected in patients with colorectal cancer in recent years.